美国 FDA 和中国 NMPA 批准 SPEVIGO ®用于治疗 12 岁以上患者的全身性脓疱型银屑病。 US FDA and China's NMPA approve SPEVIGO® for treating generalized pustular psoriasis in patients aged 12+.

勃林格殷格翰宣布，美国FDA和中国国家药品监督管理局已批准SPEVIGO®（spesolimab-sbzo）注射液用于治疗12岁及以上体重≥40公斤的全身性脓疱性银屑病（GPP）患者。 Boehringer Ingelheim announced that the US FDA and China's National Medical Products Administration have approved SPEVIGO® (spesolimab-sbzo) injection for treating generalized pustular psoriasis (GPP) in patients aged 12 and above weighing ≥40 kg. 这标志着第一个针对 GPP 患者急性和慢性治疗需求的靶向治疗。 This marks the first targeted therapy addressing the need for acute and chronic treatment of GPP patients. SPEVIGO® 目前已在 48 个国家/地区获得批准。 SPEVIGO® is currently approved in 48 countries.